Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,839,196
  • Shares Outstanding, K 225,893
  • Annual Sales, $ 2,200 M
  • Annual Income, $ 389,800 K
  • 60-Month Beta 1.08
  • Price/Sales 11.33
  • Price/Cash Flow 21.12
  • Price/Book 6.10
Trade HZNP with:

Options Overview Details

View History
  • Implied Volatility 46.02%
  • Historical Volatility 19.66%
  • IV Percentile 35%
  • IV Rank 39.02%
  • IV High 68.32% on 11/10/20
  • IV Low 31.74% on 08/12/21
  • Put/Call Vol Ratio 2.95
  • Today's Volume 2,233
  • Volume Avg (30-Day) 802
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 19,232
  • Open Int (30-Day) 15,911

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.55
  • Number of Estimates 6
  • High Estimate 1.66
  • Low Estimate 1.47
  • Prior Year 1.74
  • Growth Rate Est. (year over year) -10.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.30 +2.74%
on 09/13/21
111.70 -4.06%
on 09/02/21
-1.07 (-0.99%)
since 08/27/21
3-Month
90.85 +17.95%
on 07/08/21
111.70 -4.06%
on 09/02/21
+11.31 (+11.80%)
since 06/28/21
52-Week
66.41 +61.36%
on 12/21/20
111.70 -4.06%
on 09/02/21
+27.49 (+34.50%)
since 09/28/20

Most Recent Stories

More News
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon's R&D leadership, executives and key opinion...

HZNP : 107.16 (-2.55%)
Horizon Therapeutics plc Announces Data Showing UPLIZNA(R) (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, indicating UPLIZNA may provide durable efficacy and a favorable...

HZNP : 107.16 (-2.55%)
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX,...

REGN : 605.00 (-2.27%)
VRTX : 181.60 (-0.99%)
MRNA : 384.21 (-6.02%)
HZNP : 107.16 (-2.55%)
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

Sector ETF report for PTH

PTH : 162.01 (-3.98%)
MRNA : 384.21 (-6.02%)
IDXX : 626.85 (-3.56%)
HZNP : 107.16 (-2.55%)
XLV : 127.87 (-1.71%)
VHT : 249.22 (-1.99%)
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis

-- Next-generation sequencing data delivers personalized rare disease therapies in an equitable manner to underrepresented communities --

HZNP : 107.16 (-2.55%)
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

/PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment...

HZNP : 107.16 (-2.55%)
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

REGN : 605.00 (-2.27%)
IRWD : 13.36 (-0.96%)
HZNP : 107.16 (-2.55%)
AERI : 11.49 (-3.85%)
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

VRTX : 181.60 (-0.99%)
QGEN : 51.52 (-2.13%)
MRNA : 384.21 (-6.02%)
HZNP : 107.16 (-2.55%)
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women(TM) by Fortune and Great Place to Work(R)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women(TM) list for the first time by Fortune and Great Place to Work(R). The Best Workplaces...

HZNP : 107.16 (-2.55%)
3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock

Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.

HZNP : 107.16 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. ...

See More

Key Turning Points

3rd Resistance Point 111.60
2nd Resistance Point 110.68
1st Resistance Point 108.92
Last Price 107.16
1st Support Level 106.24
2nd Support Level 105.32
3rd Support Level 103.56

See More

52-Week High 111.70
Last Price 107.16
Fibonacci 61.8% 94.40
Fibonacci 50% 89.06
Fibonacci 38.2% 83.71
52-Week Low 66.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar